Acheampong Deasmond O, Adokoh Christian K, Ampomah Paulina, Agyirifor Daniel S, Dadzie Isaac, Ackah Francis A, Asiamah Ernest A
Department of Biomedical Sciences, School of Allied Health Sciences, University of Cape Coast, Cape Coast. Ghana.
Department of Forensic Sciences, School of Biological Sciences, University of Cape Coast, Cape Coast. Ghana.
Protein Pept Lett. 2017;24(5):456-465. doi: 10.2174/0929866524666170120095128.
Antibodies have become the preferred therapeutic treatment option for cancers. Antibody therapy is associated with low toxic profile and specific in its activity, unlike chemotherapy and radiotherapy. Types of tumor are known to express multiple receptors that cross-talk to activate perpetual growth, proliferation and metastasis, and inhibit apoptosis in such tumors. Bispecific antibodies (BsAbs) are therefore the preferred agent for the treatment of such cancers due to its unique characteristics. This review discusses up to date therapeutic potentials of BsAbs.
抗体已成为癌症治疗的首选治疗方案。与化疗和放疗不同,抗体疗法具有低毒性且活性具有特异性。已知肿瘤类型会表达多种相互作用以激活持续生长、增殖和转移并抑制此类肿瘤细胞凋亡的受体。因此,双特异性抗体(BsAbs)因其独特特性而成为治疗此类癌症的首选药物。本综述讨论了双特异性抗体最新的治疗潜力。